| Literature DB >> 25043503 |
Sarah Schiekirka, Sven Anders, Tobias Raupach1.
Abstract
BACKGROUND: Estimating learning outcome from comparative student self-ratings is a reliable and valid method to identify specific strengths and shortcomings in undergraduate medical curricula. However, requiring students to complete two evaluation forms (i.e. one before and one after teaching) might adversely affect response rates. Alternatively, students could be asked to rate their initial performance level retrospectively. This approach might threaten the validity of results due to response shift or effort justification bias.Entities:
Mesh:
Year: 2014 PMID: 25043503 PMCID: PMC4112834 DOI: 10.1186/1472-6920-14-149
Source DB: PubMed Journal: BMC Med Educ ISSN: 1472-6920 Impact factor: 2.463
Figure 1Study design (see text for details).
Student self-assessments for 33 specific learning objectives (1 = most positive rating; 6 = most negative rating)
| Acute bronchitis | 4.35 ± 1.31 | 4.75 ± 1.24 | 5.00 ± 0.99 | 4.56 ± 1.13 | 3.21 ± 1.46 | 3.09 ± 1.06 |
| Pericarditis | 5.90 ± 0.30 | 5.51 ± 1.13 | 5.50 ± 1.11 | 5.50 ± 1.27 | 2.74 ± 1.48 | 2.34 ± 1.45 |
| Acute arterial occlusion | 3.82 ± 1.46 | 4.13 ± 1.40 | 4.10 ± 1.30 | 4.53 ± 1.32 | 1.74 ± 1.31 | 1.69 ± 0.93 |
| Acute myocardial infarction | 3.14 ± 1.41 | 3.63 ± 1.62 | 3.93 ± 1.40 | 4.41 ± 1.37 | 1.36 ± 0.53 | 1.63 ± 1.04 |
| Aortic aneurysm & dissection | 5.19 ± 1.38 | 4.91 ± 1.53 | 5.40 ± 1.17 | 5.38 ± 1.21 | 1.55 ± 0.77 | 1.47 ± 1.05 |
| Aortic stenosis | 4.58 ± 1.35 | 4.94 ± 1.36 | 5.22 ± 1.15 | 5.19 ± 1.15 | 1.74 ± 0.99 | 2.00 ± 1.08 |
| Asthma | 5.14 ± 1.10 | 5.31 ± 1.13 | 5.02 ± 1.33 | 5.34 ± 1.34 | 2.05 ± 1.13 | 2.13 ± 0.98 |
| Atherosclerosis | 2.94 ± 1.38 | 3.39 ± 1.38 | 3.32 ± 1.29 | 3.84 ± 1.51 | 1.79 ± 0.81 | 1.94 ± 1.22 |
| Chronic bronchitis | 4.28 ± 1.48 | 4.66 ± 1.37 | 4.56 ± 1.34 | 4.78 ± 1.29 | 2.29 ± 1.18 | 2.03 ± 1.09 |
| COPD | 5.42 ± 0.80 | 5.34 ± 1.23 | 5.29 ± 1.10 | 5.34 ± 1.31 | 1.60 ± 0.94 | 1.94 ± 1.01 |
| Pulmonary emphysema | 5.42 ± 0.68 | 5.48 ± 1.02 | 5.29 ± 1.03 | 5.19 ± 1.42 | 2.64 ± 1.48 | 2.31 ± 1.23 |
| Endocarditis | 5.55 ± 0.97 | 5.52 ± 1.17 | 5.51 ± 1.31 | 5.66 ± 1.13 | 2.02 ± 1.39 | 1.91 ± 1.15 |
| Tetralogy of Fallot | 5.18 ± 1.33 | 5.01 ± 1.61 | 5.12 ± 1.74 | 5.38 ± 1.52 | 1.57 ± 1.35 | 1.41 ± 1.23 |
| Congestive heart failure | 4.59 ± 1.31 | 5.07 ± 1.34 | 4.76 ± 1.48 | 5.41 ± 1.24 | 1.64 ± 0.79 | 1.59 ± 1.10 |
| Arterial hypertension | 3.58 ± 1.42 | 4.56 ± 1.21 | 4.44 ± 1.48 | 4.69 ± 1.33 | 3.14 ± 1.49 | 2.34 ± 1.23 |
| Influenza | 2.87 ± 1.44 | 3.81 ± 1.40 | 4.27 ± 1.58 | 4.59 ± 1.48 | 2.48 ± 1.35 | 2.47 ± 1.22 |
| Cardiomyopathy | 5.73 ± 0.59 | 5.55 ± 0.93 | 5.50 ± 1.18 | 5.59 ± 1.16 | 2.64 ± 1.21 | 2.53 ± 1.11 |
| Coronary artery disease | 2.93 ± 1.53 | 3.23 ± 1.32 | 2.85 ± 1.30 | 3.63 ± 1.58 | 1.21 ± 0.47 | 1.31 ± 1.00 |
| Pulmonary embolism | 5.67 ± 0.61 | 5.68 ± 0.83 | 5.37 ± 0.99 | 5.22 ± 1.39 | 2.45 ± 1.15 | 2.41 ± 1.16 |
| Mitral regurgitation | 4.69 ± 1.22 | 4.99 ± 1.26 | 4.90 ± 1.15 | 5.28 ± 1.05 | 2.07 ± 0.89 | 2.25 ± 1.02 |
| Myocarditis | 4.96 ± 1.13 | 5.28 ± 1.03 | 5.15 ± 1.26 | 5.44 ± 1.16 | 2.38 ± 1.06 | 2.31 ± 0.93 |
| Peripheral artery disease | 4.95 ± 1.38 | 5.21 ± 1.28 | 4.83 ± 1.47 | 4.88 ± 1.54 | 2.17 ± 1.31 | 2.47 ± 1.61 |
| Patent foramen ovale | 5.45 ± 0.94 | 5.45 ± 1.06 | 5.46 ± 1.00 | 5.66 ± 1.13 | 2.90 ± 1.59 | 2.69 ± 1.53 |
| Pleural effusion | 5.32 ± 0.89 | 5.33 ± 1.02 | 5.07 ± 1.37 | 5.41 ± 1.16 | 2.69 ± 1.28 | 2.91 ± 1.25 |
| Pneumonia | 4.59 ± 1.43 | 4.85 ± 1.30 | 4.98 ± 1.29 | 5.31 ± 1.12 | 2.31 ± 1.35 | 2.41 ± 1.39 |
| Pneumothorax | 3.48 ± 1.36 | 3.99 ± 1.37 | 4.32 ± 1.46 | 4.59 ± 1.39 | 2.33 ± 1.20 | 2.19 ± 1.15 |
| Pulmonary hypertension | 4.49 ± 1.37 | 5.30 ± 1.01 | 5.10 ± 1.18 | 5.22 ± 1.39 | 3.36 ± 1.64 | 3.28 ± 1.33 |
| Interstitial lung disease | 5.60 ± 0.87 | 5.74 ± 0.70 | 5.69 ± 0.72 | 5.66 ± 1.04 | 3.98 ± 1.56 | 4.69 ± 1.31 |
| Cardiac arrhythmias | 4.25 ± 1.61 | 4.88 ± 1.48 | 5.19 ± 1.19 | 5.31 ± 1.38 | 2.05 ± 1.04 | 2.16 ± 1.44 |
| Cardiogenic shock | 4.55 ± 1.20 | 4.76 ± 1.23 | 4.76 ± 1.19 | 4.97 ± 1.20 | 3.00 ± 1.23 | 2.88 ± 1.19 |
| Rheumatic fever | 5.00 ± 1.13 | 5.51 ± 0.98 | 5.50 ± 0.99 | 5.50 ± 0.95 | 3.02 ± 1.41 | 2.91 ± 1.15 |
| Smoking | 5.63 ± 0.71 | 5.37 ± 1.34 | 5.43 ± 1.25 | 5.50 ± 1.30 | 1.86 ± 1.46 | 2.31 ± 1.66 |
| Tuberculosis | 5.40 ± 0.84 | 5.49 ± 0.88 | 5.14 ± 1.20 | 5.34 ± 1.21 | 3.45 ± 1.66 | 3.44 ± 1.50 |
Data are presented as means ± standard deviations. COPD, chronic obstructive pulmonary disease.
Figure 2Impact of the time-point of data collection on initial performance level ratings for 33 learning objectives.
Figure 3Correlation between prospective and retrospective performance gain values for 33 learning objectives (r = 0.975; p < 0.001).
Figure 4Impact of the design of the data collection tool on (A) thentest and (B) posttest ratings for 33 learning objectives.
Figure 5Correlation of retrospective performance gain values between group A (sequential data collection) and group B (direct comparison; r = 0.890; p < 0.001).